The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Importance Heart failure with reduced ejection fraction is a progressive clinical syndrome,
and many patients' condition worsen over time despite treatment. Patients with more severe …

Background The relationship between the benefits of empagliflozin in heart failure with
reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT …

Abstract Background In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in Heart Failure)(n= 8,256), the cardiac myosin …

Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …

Las guías de práctica clínica (GPC) tienen como objetivo reunir y evaluar toda la evidencia
relevante disponible durante el proceso de elaboración sobre un tema particular para …

Major changes have occurred in these last years in heart failure (HF) management.
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …